Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world.

Front Oncol · 2026 · PMC13229803 · PMID 42245721

Europe PMC DOI

hedged sentence

0.0880

closest p · 1.8× alpha

0.0880

boldest claim

The sentences

showed a trendP = 0.088so close (0.05 < p ≤ 0.1)

50.0%, P = 0.035), and also showed a trend toward longer mPFS (6.1 months vs. 3.3 months, Log-rank P = 0.088).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.